

Continue

Gestational diabetes screening guidelines acog

National Diabetes Information. Clearinghouse (NDIC). ﷺ 2011 Metzger BE, Dr. Kuster, Minutes of the 4th International Working Shop Conference on Gestational Diabetes Diabetes Diabetes Care. 1998. 21 (Supplement 2): B1-B167.Ceci TL, Brown AJ, Fine Ross MN. Gestational Diabetes Clinical Diabetes.2005. 23:17-24.Bab GR, Kartik M, Ravi D. What are the reasons why other pregnant women revisit public hospitals for research? BMC pregnancy birth. September 12, 2018 18 (1): 369. [Medline]. Ferrat E, Wilman K, Frische L, Linder K, Matt Hussin H, Schrager F, and other gestational diabetes changes fetal heart rate variability during oral glucose tolerance tests: fetal magnetic calpography studies. Biog. November 124, 2017 (12): 1891-1898. [Medline]. [Full text]. Jovanovic L, Pettitt DJ. Gestational diabetes mellitus. Jama. November 28, 2001 286 (20): 2516-8. [Medline]. Metzger BE, Buchanan TA. Overview and Recommendations of the 5th International Workshop on Gestational Diabetes Diabetes Care. 2005. 30 (Suppl. 2): S251-260.Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jefferies WS, Robinson JS. Effects of treatment of gestational diabetes mellitus on pregnancy outcomes N Engle J Med 2005 June 16, 352 (24): 2477-86. [Medline]. Landon MB, Spon CY, Tom E, Carpenter MW, Lamine SM, Casey B. Multi-facility, randomized trial of treatment for mild gestational diabetes. N Engle J Med 2009 October 1, 361 (14): 1339-48. [Medline]. Lowe LP, Metzger BE, Dyer AR, Rowe J, McCanns DR, Lappin TR, others hyperglycemia and adverse pregnancy outcomes (HAPO) studies: Association between maternal A1C and glucose and pregnancy outcomes. Diabetes care. March 35, 2012 (3): 574-80. [Medline]. [Full text]. American Diabetes Association Diabetes - Medical level diabetes care in 2011. 2011. 34 (Suppl. 1): S11-61.McIntyre HD, Metzger BE, Kustern DR, Dyer AR, Hadden DR, Hodd M, and other counters: Establishing consensus in the diagnosis of GDM following the HAPO study Cardia Brep 2014 June 14 (6): 497. [Medline]. [Full text]. Metzger BE, Gabbe SG, Person B, Buchanan TA, Catalano PA. The International Association of Diabetes and Pregnancy groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes care. March 33, 2010 (3): 676-82. [Medline]. American College of Obstetricians and Gynecologists.Opinion of the Screening and Diagnostic Committee on Gestational Diabetes No. 504. American College of Obstetricians and Gynecologists.Obstedt Günekol 2011.118:751-3. Available at gestational diabetes www.idf.org. . 2017; Gestational diabetes. www.cdc.gov. available at . Accessed: July 25, 2017. Jackson SL, Sapo SE, S times LR, Olson DE, Narayan KMV, Long Q, Other Glucose Challenge test screeningsDiabetes and Early Diabetes.Diabet Med May 34, 2017 (5):716-724. [Medline]. [Full text]. Thiu J, McPhee AJ, Crowther CA, Middleton P. Screening and subsequent management of gestational diabetes to improve mother and infant health. Cochrane Database System February 11, 2014 2:CD007222. [Medline]. Carson MP, Morgan B, Gasman D, Brown M, Rotenberg K, Wisner TA. SUGAR: Discover undiagnosed glucose abnormality results - a new protocol that increases post-baby testing in women with gestational diabetes. Am J Perinator. August 5, 2014 [Medline]. Alert: LabCorp COVID-19 is a fully integrated portfolio of antibody testing LabCorp and its specialized testing groups >>> specialized testing labs available nationwide. Up to 7% of pregnancies are complicated by diabetes, and the rate of gestational diabetes is rising worldwide as obesity and sitting lifestyles increase. Gestational diabetes increases the risk of developing gestational hypertension, preeclampsia, cesarean deliveries, and diabetes later in life. There is a debate about the diagnosis and treatment of gestational diabetes, even with a large study on the subject. The American College of Obstetricians and Gynecologists (ACOG) has published guidelines that provide recommendations based on quality studies and identify current gaps in knowledge. Gestational diabetes should be treated with nutritional therapy. If necessary, the drug should also be used for the mother and fetus. Studies have shown a significant reduction in the treatment of gestational diabetes and serious complications. Nutritional therapy includes nutritional counseling, personalized nutrition plans, and moderate exercise programs aimed at achieving normauricemia, preventing quetosis, promoting sufficient weight gain, and contributing to the well-being of the fetus. If nutritional therapy alone cannot meet the target glucose level, you should start medical therapy. There is no conclusive evidence to guide the timing of initiating the drug. . . insulin was the standard medical therapy for gestational diabetes, but insulin and oral medications (e.g., glybride, metformin [glucophage]) are equally effective and appropriate for first-line therapy. Limited or contradictory evidence All pregnant women should be screened for gestational diabetes using history, clinical risk factors, or glucose screening tests. Screening for gestational diabetes is usually done in pregnancies between 24 and 28 weeks. Early screening is recommended for women with risk factors (i.e., a history of gestational diabetes, known glucose metabolic disorders, or obesity [body mass index above 30]). If the early screening results are negative, the screening should be repeated in pregnancy from 24 to 28 weeks. The screening approach, widely used in the United States, involves an initial venous glucose measurement of 1 hour after the administration of 50 g of oral glucose solution. Women who meet or exceed screening thresholdsThe test then takes a 100g, 3-hour oral glucose tolerance test. While there is insufficient data recommended for cesarean births when suspected of macrosomire to reduce birth trauma, macrosomire is more common in gestational diabetes and shoulder dystasia is more common in large newborns who have gestational diabetes. Therefore, if gestational diabetes is diagnosed and the fetus is estimated to weigh more than 4,500 g (9 pounds, 15 ounces), it is reasonable to discuss the option of cesarean birth. Consensus and Expert Opinion The screening threshold for the 1-hour glucose challenge ranged from 130 mg per hour (7.2 millimoles per L) to 140 mg / dL (7.8 millimoles per L) and showed a variety of sensitivities and specificities. Because there is no clear evidence to determine the best threshold, doctors should choose dL as one consistent cutoff of 135 mg/dL (7.5 mmol per L) or 140 mg. Factors such as the prevalence of the community of gestational diabetes should be taken into account in the decision, as well as in the 3-hour oral glucose resistance test, one set of diagnostic criteria cannot be recommended. Doctors should select a single diagnostic criterion for plasma or serum glucose levels specified by Carpenter and Kustan standards, or plasma levels established by the National Diabetes Data Group. There is not enough evidence to determine the optimal frequency of glucose monitoring, but the general recommendation is 4 times daily (fasting and 1-2 hours after each meal). Monitoring can be adjusted after glucose levels are well controlled by the diet. Women with gestational diabetes who have good glycemic control and no other complications can be treated during pregnancy. Most women with good glycemic control with medical therapy do not need to give birth before 39 weeks of pregnancy. All women with gestational diabetes should be screened for 6-12 weeks after childbirth for diabetes, fasting glucose disorder, or impaired glucose glucose. Women with positive screening results should be introduced to preventive therapy, and women with negative screening results should undergo follow-up tests every three years. Fasting plasma glucose test or 75 g 2-hour oral glucose glucose resistance test is suitable for post-post screening. Guideline Source: Using the U.S. College Evidence Assessment System for Obstetricians and Gynecologists?Yes Literary Searches Are Explained?Yes, Guidelines Developed by Participants Without Any Relevant Financial Relationships with the Industry?Undecered Public Source: Obstetricians and Gynecology, Available August 2013: 2 U.S. Preventive Services Task Force (USPSTF) RecommendedFor hepatitis C virus (HCV) infection in people at high risk of infection. The USPSTF also recommends that adults born between 1945 and 1965 be provided with a one-time screening for HCV infection (Table 1). B Recommendation. For more information about risk factors for HCV infection, see Clinical considerations. HCV is the most common chronic blood-borne pathogen in the United States and is the leading cause of complications from chronic liver disease. The prevalence of anti-HCV antibodies in the United States is about 1.6% in non-institutionalized people. According to data from 1999 to 2008, about three-quarter of U.S. patients with HCV infection were born between 1945 and 1965, The peak morbidity rate for patients aged 40-49 until January 1 was 4.3%, and the most important risk factor for HCV infection was past or present injection use, with most studies reporting a prevalence of more than 50%. The incidence of HCV infection exceeded 200,000 cases per year in the 1980s, but decreased to 25,000 cases per year in 2001. According to the Centers for Disease Control and Prevention, there were an estimated 16,000 new HCV cases in 2009 and an estimated 15,000 deaths in 2007. Hepatitis C-related terminal liver disease is the most common indication of liver transplantation in U.S. adults, accounting for more than 30 percent of cases. Research suggests that about one-second of the incidence of recently observed hepatocellular carcinoma is associated with the acquisition of HCV infection 2-40 years ago. In screening strategies targeting people with risk factors for HCV infection (past or present injectable drug use, sex with injectable drug users, blood transfusions before 1992, etc.), a small number (fewer than 20 people) required for screening to identify one case (less than 20 people) of HCV infection associated with high sensitivity (above 90 percent) The number of cases of HCV infection that needs to be screened to detect them is large, but remains highly accurate in low prevalence populations. The USPSTF also found sufficient evidence that various noninvasive tests are very good diagnostic accuracy friendly in the diagnosis of fibrosis or cirrhosis. However, the USPSTF found sufficient evidence that antiviral regimens lead to sustained viral responses and improve clinical outcomes. The USPSTF found insufficient evidence that counseling or immunization of HCV-infected patients for other infections improves health outcomes, reducing HCV transmission or changing high-risk behavior. USPSTF found inadequateKnowledge of the positive status of HCV infection reduces risky behavior. The USPSTF also found insufficient evidence that labor management and breastfeeding strategies in HCV-positive women are effective in reducing the risk of mother-to-child infection. Given the accuracy of screening tests and the potential for effective intervention against HCV infection, the USPSTF concludes that screening is of moderate benefit to populations at high risk of infection. The USPSTF concludes that one-off screening in all U.S. adults born between 1945 and 1965 is also of moderate benefit. Detection and early intervention harm The USPSTF has found limited evidence of the harms of screening for HCV. Potential harms of screening include anxiety, patient display, and feelings of stigma. The USPSTF has found sufficient evidence on the harms associated with diagnostic assessments used to guide treatment decisions (liver biopsies). These harms include bleeding, infection, and severe pain in about 1% of those who have had liver biopsies and deaths in less than 0.2%. However, the use of liver biopsies to guide treatment decisions is decreasing, and noninvasive tests are accurate enough to diagnose fibrosis and cirrhosis. Therefore, the absolute risk to those currently diagnosed with HCV infection and subsequent treatment is probably reduced. The USPSTF found sufficient evidence that antiviral therapy regimens are associated with high harm rates such as fatigue, headaches, flu-like symptoms, hematological events, and rashes. However, antiviral therapy is given for a defined period of time, serious adverse events are rare, adverse events are self-limiting, and are typically resolved after treatment is discontinued. The USPSTF found sufficient evidence that the harm of these treatments was small. The USPSTF Assessment USPSTF concludes with moderate certainty that HCV infection screening and one-off screening of adults at high risk of infection in the 1945-1965 birth cohort have moderate net benefits. This recommendation applies to all asymptotic adults without known liver disease or functional abnormalities. Risk assessment The most important risk factor for HCV infection is the use of past or present injectable drugs. Another established risk factor for HCV infection is that it received a blood transfusion before 1992. With the implementation of a screening program for blood donation blood, blood transfusions are no longer an important cause of HCV infection. In contrast, 60% of new HCV infections occur in those who report the use of injectable drugs within the last six months. Additional risk factors include long-term hemodialysis, HCV infection, incarceration, intranasal drug use, obtaining unregulated tattoos, and other percutaneous exposures, such as practitioners and undergoing surgery before universal precautions. Evidence for tattoos and other transdermal skinRisk factors for HCV infection are limited. The relative importance of these additional risk factors may vary based on geographical location and other factors. 1 large population-based study reports an independent association between high-risk sexual behavior (sex with multiple sex partners, unprotected sex, or sex with a person with HCV infection or injectable drugs) and HCV infection. However, HCV seems to be transmitted inefficiently through sexual contact, and the observed association may be disrupted by other high-risk behaviors. In 1998, the prevalence of anti-HCV antibodies was highest in those with significant direct transdermal exposure (60% to 90%), such as injectable drug users and hemophilia patients (60% to 90%). Among those who engage in high-risk sexual behavior (1% to 10%), recipients of blood transfusions (6%), those with less percutaneous exposure frequency, and patients with abnormal results in liver function tests tested for reasons other than HCV screening (measurements of asparagine transamines, alanine transamines, and bilirubin), there are many tests for HCV infection and possible case finding rather than screening. This recommendation is out of scope. In 2010, the total incidence of acute HCV infection was 0.3 cases per 100,000 people, varying by race and ethnicity. The incidence of acute hepatitis C was lowest among Asian or Pacific Islanders and highest among American Indians and Alaska Natives. Black mortality rates are highest from HCV, between 6.5 and 7.8 deaths per 100,000 people, according to data from 2004 to 2008. Those born between 1965 are likely to be diagnosed with HCV infection, possibly because they received a blood transfusion before screening was introduced in 1992 or have a history of other risk factors for exposure decades ago. Risk-based approaches can miss detection of a significant percentage of HCV-infected people in the birth cohort because they have no knowledge of patient disclosure or previous risk status. As a result, a one-time screening of HCV infection in the birth cohort can identify patients infected in the early stages of the disease who can benefit from treatment before developing complications from liver damage. The USPSTF concluded that the benefits of screening for HCV infection in those in the birth cohort are probably similar to those at high risk of infection. Birth cohort screening is less efficient than risk-based screening and requires more peopleScreened to identify one patient with HCV infection. Nevertheless, the total number of Americans who will probably benefit from birth cohort screening is higher than the number who would benefit from risk-based screening. The USPSTF recognizes that increased screening and the resulting increase in diagnosis and treatment can increase overall harm, as not all treated persons benefit from treatment (overdiagnosa). The USPSTF compared this potential harm against the potential harm of under-treatment resulting from underdiagnosy. Future research is expected to reduce over-treatment by revealing who is most likely to benefit from early diagnosis and treatment. However, given that those in the birth cohort have been living with HCV infections for more than 20 years, the potential benefits of screening and early treatment will probably be highest now and in the near future, before declining. After comparing the competing harms of over-treatment and underdiagnosy, the USPSTF recommends one-time screening of this cohort. Screening tests Following anti-HCV antibody tests, polymerase chain reaction tests for viremia are accurate in identifying patients with chronic HCV infection. Various noninvasive tests with good diagnostic accuracy may replace liver biopsies to diagnose fibrosis or cirrhosis. Screening intervals Those in the birth cohort and those who are at risk for potential exposure before universal blood screening and who are otherwise not at high risk should only be screened once. People at continued risk of HCV infection (injectable drug users) should be screened regularly. The USPSTF found no evidence of how often screening occurs in those who continue to be at risk of new HCV infections. Screening Conduct The USPSTF believes that screening is voluntary and should only be done with the patient's knowledge and understanding that an HCV test is planned. Patients must be notified orally or in writing that HCV testing will take place (opt-out screening) unless they decline. The USPSTF further believes that before HCV screening, patients should be treated with a description of HCV infection, how it can (and cannot be obtained), the meaning of positive and negative test results, and the benefits and harms of treatment. Patients should

also be offered the opportunity to ask questions and decline the test. Treatment The purpose of the antiviral treatment regimen is to prevent long-term health complications of chronic HCV infection (cirrhosis, liver failure, hepatocellular carcinoma, etc.). The combination of pegulified interferon (alpha-2a or alpha-2b) and ribavirin is the standard treatment for HCV infection. In 2011, the U.S. Food and Drug Administration approved protease inhibitors of bosepreville and terrapreville for the treatment of HCV geno type 1 infection, a major geno type in United.The trial found an increase in persistent viral response rates in patients with HCV geno type 1 infection who received triple therapy consisting of pegulate interferon, ribavirin, and bosseprevir or teraprevir, compared to dual therapies consisting of pegulized interferon and ribavirin. The evidence lacks the comparative effect of current antiviral treatments on long-term clinical outcomes. Regimens with protease inhibitors are usually shorter durations than double therapy (24 or 28 weeks vs. 48 weeks). Triple therapy with protease inhibitors is associated with an increased risk of hematological events (e.g., anemia, eelocytopenia, thrombocytopenia, especially with boceprebyr) and rash (terapreville) compared to double therapy. These adverse events are self-limiting and are usually resolved after discontinuation of treatment.